OncoMatch/Clinical Trials/NCT06339060
An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).
Is NCT06339060 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Experimental: Arm 1 Organ preservation and Active Comparator: Arm 2 Surgery for esophageal cancer.
Treatment: Experimental: Arm 1 Organ preservation · Active Comparator: Arm 2 Surgery — Patients with locally advanced esophageal squamous cell carcinoma will randomly assigned to receive neoadjuvant chemo-radiotherapy combined with immunotherapy post organ preservation strategy (experimental group) or neoadjuvant chemo-radiotherapy followed by surgery (control group). The 3-year overall survival rate is the primary outcome.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CT2-T4A, N0-N+
cT2-T4a,N0-N+,M0 resectable esophageal squamous cell carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Cannot have received: radiotherapy
Cannot have received: targeted therapy
Cannot have received: immunotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06339060 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage CT2-T4A or N0-N+ is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages